Yourgene Health (OTC:VILGF – Get Rating) had its price objective cut by Stifel Nicolaus from GBX 20 ($0.25) to GBX 15 ($0.19) in a report issued on Tuesday, The Fly reports.
Yourgene Health Company Profile (Get Rating)
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down's syndrome and other genetic disorders in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products.
- Get a free copy of the StockNews.com research report on Yourgene Health (VILGF)
- Synchrony Financial Stock is Ready to Slingshot Back Up
- Why These 3 Stocks Matter Most in the Dow
- Cisco Systems Stock Bestows Another Buy the Dip Opportunity
- 3 Stocks Near 52-Week Highs That Still Look Cheap
- MarketBeat Podcast: Profit From Diversifying Trading Strategies
Receive News & Ratings for Yourgene Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yourgene Health and related companies with MarketBeat.com's FREE daily email newsletter.
